

ASX RELEASE

Netherlands trial using the Volpara®Density™ clinical application reports initial results at the European Congress of Radiology 2019

Highlights:

- **One of the largest-ever trials using VolparaDensity to determine if a combination of mammography, density screening and breast MRI is effective in reducing interval cancer (detected between screenings)**
- **Initial results show a dramatic drop in interval cancers in extremely dense breasts when using breast x-ray, VolparaDensity and then breast MRI**
- **Full results to be published in a peer-reviewed journal**

Wellington, NZ, 4th March 2019: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, today announces that first results of the DENSE trial—a major study using VolparaDensity—have been presented by Professor Carla van Gils at the European Congress on Radiology (ECR) in Vienna on Friday 1st March 2019, and provide further evidence of the significance of breast density as a risk factor for a missed cancer.

As previously announced, the DENSE trial, a study started in 2011 in The Netherlands, is funded by Bayer and multiple Dutch organizations, and features the use of VolparaDensity to select women for breast MRI on the basis of their breasts' being judged extremely dense.

Professor van Gils talk reminded the community of the significance of breast density as measured by VolparaDensity as a risk factor for a missed cancer, especially in extremely dense breasts, where the sensitivity of mammography drops towards 61% (i.e., the probability that if a cancer is present it gets picked up by a radiologist looking at a mammogram).

She also noted that in extremely dense breasts the number of cancers found between screenings ("interval cancers") is 4.4 per thousand. Interval cancers tend to be bigger and therefore deadlier than smaller cancers. The aim of the DENSE trial is to see if using breast MRI is cost-effective in reducing that number of interval cancers.

The first results, presented at ECR and to be submitted to a major journal this week, demonstrate that the number of interval cancers reported drops dramatically by using breast x-ray, VolparaDensity and then breast MRI. In addition, this drop is accompanied by a relatively low number of false positives (i.e., the number of women who have biopsies that turn out not to be cancer).

Dr Ralph Highnam, CEO of Volpara, said of the DENSE study: "This is a large trial involving approximately 40,000 women, with massive implications for breast cancer screening globally. Screening programs have been waiting for randomized control trials to show the benefit of density-based screening. Finally, they now have a way forward to optimize their screening protocols. This will lead to the early identification of many more cancers and a reduction in the devastating impact of breast cancer. It will also mean increasing international interest in automated breast density solutions such as VolparaDensity."

ENDS.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 36 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com